1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Heparin-induced Thrombocytopenia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Activated Factor X Inhibitors Heparin-Induced Thrombocytopenia Treatment
1.2.3 Direct Thrombin Inhibitors Heparin-Induced Thrombocytopenia Treatment
1.2.4 Heparinoids Heparin-Induced Thrombocytopenia Treatment
1.2.5 Fondaparinux Heparin-Induced Thrombocytopenia Treatment
1.2.6 Heparin And Vitamin K Antagonist Therapy Heparin-Induced Thrombocytopenia Treatment
1.3 Market by Application
1.3.1 Global Heparin-induced Thrombocytopenia Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Heparin-induced Thrombocytopenia Treatment Market Perspective (2018-2029)
2.2 Heparin-induced Thrombocytopenia Treatment Growth Trends by Region
2.2.1 Global Heparin-induced Thrombocytopenia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Heparin-induced Thrombocytopenia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Heparin-induced Thrombocytopenia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Heparin-induced Thrombocytopenia Treatment Market Dynamics
2.3.1 Heparin-induced Thrombocytopenia Treatment Industry Trends
2.3.2 Heparin-induced Thrombocytopenia Treatment Market Drivers
2.3.3 Heparin-induced Thrombocytopenia Treatment Market Challenges
2.3.4 Heparin-induced Thrombocytopenia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Heparin-induced Thrombocytopenia Treatment Players by Revenue
3.1.1 Global Top Heparin-induced Thrombocytopenia Treatment Players by Revenue (2018-2023)
3.1.2 Global Heparin-induced Thrombocytopenia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Heparin-induced Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Heparin-induced Thrombocytopenia Treatment Revenue
3.4 Global Heparin-induced Thrombocytopenia Treatment Market Concentration Ratio
3.4.1 Global Heparin-induced Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Heparin-induced Thrombocytopenia Treatment Revenue in 2022
3.5 Heparin-induced Thrombocytopenia Treatment Key Players Head office and Area Served
3.6 Key Players Heparin-induced Thrombocytopenia Treatment Product Solution and Service
3.7 Date of Enter into Heparin-induced Thrombocytopenia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Heparin-induced Thrombocytopenia Treatment Breakdown Data by Type
4.1 Global Heparin-induced Thrombocytopenia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Heparin-induced Thrombocytopenia Treatment Forecasted Market Size by Type (2024-2029)
5 Heparin-induced Thrombocytopenia Treatment Breakdown Data by Application
5.1 Global Heparin-induced Thrombocytopenia Treatment Historic Market Size by Application (2018-2023)
5.2 Global Heparin-induced Thrombocytopenia Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
6.2 North America Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
6.4 North America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
7.2 Europe Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
7.4 Europe Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
9.2 Latin America Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
9.4 Latin America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer Healthcare Pharmaceuticals Inc.
11.1.1 Bayer Healthcare Pharmaceuticals Inc. Company Detail
11.1.2 Bayer Healthcare Pharmaceuticals Inc. Business Overview
11.1.3 Bayer Healthcare Pharmaceuticals Inc. Heparin-induced Thrombocytopenia Treatment Introduction
11.1.4 Bayer Healthcare Pharmaceuticals Inc. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.1.5 Bayer Healthcare Pharmaceuticals Inc. Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Heparin-induced Thrombocytopenia Treatment Introduction
11.2.4 Pfizer Inc. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.2.5 Pfizer Inc. Recent Development
11.3 Janssen Pharmaceuticals, Inc.
11.3.1 Janssen Pharmaceuticals, Inc. Company Detail
11.3.2 Janssen Pharmaceuticals, Inc. Business Overview
11.3.3 Janssen Pharmaceuticals, Inc. Heparin-induced Thrombocytopenia Treatment Introduction
11.3.4 Janssen Pharmaceuticals, Inc. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.3.5 Janssen Pharmaceuticals, Inc. Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Heparin-induced Thrombocytopenia Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Eisai Co., Ltd
11.5.1 Eisai Co., Ltd Company Detail
11.5.2 Eisai Co., Ltd Business Overview
11.5.3 Eisai Co., Ltd Heparin-induced Thrombocytopenia Treatment Introduction
11.5.4 Eisai Co., Ltd Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.5.5 Eisai Co., Ltd Recent Development
11.6 LEO Pharma A/S
11.6.1 LEO Pharma A/S Company Detail
11.6.2 LEO Pharma A/S Business Overview
11.6.3 LEO Pharma A/S Heparin-induced Thrombocytopenia Treatment Introduction
11.6.4 LEO Pharma A/S Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.6.5 LEO Pharma A/S Recent Development
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Detail
11.7.2 Mylan N.V. Business Overview
11.7.3 Mylan N.V. Heparin-induced Thrombocytopenia Treatment Introduction
11.7.4 Mylan N.V. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.7.5 Mylan N.V. Recent Development
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Detail
11.8.2 Sanofi S.A. Business Overview
11.8.3 Sanofi S.A. Heparin-induced Thrombocytopenia Treatment Introduction
11.8.4 Sanofi S.A. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.8.5 Sanofi S.A. Recent Development
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.9.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.9.3 Teva Pharmaceutical Industries Ltd. Heparin-induced Thrombocytopenia Treatment Introduction
11.9.4 Teva Pharmaceutical Industries Ltd. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.9.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Detail
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Heparin-induced Thrombocytopenia Treatment Introduction
11.10.4 Fresenius Kabi AG Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.10.5 Fresenius Kabi AG Recent Development
11.11 Syntex S.A.
11.11.1 Syntex S.A. Company Detail
11.11.2 Syntex S.A. Business Overview
11.11.3 Syntex S.A. Heparin-induced Thrombocytopenia Treatment Introduction
11.11.4 Syntex S.A. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.11.5 Syntex S.A. Recent Development
11.12 Celgene Corporation
11.12.1 Celgene Corporation Company Detail
11.12.2 Celgene Corporation Business Overview
11.12.3 Celgene Corporation Heparin-induced Thrombocytopenia Treatment Introduction
11.12.4 Celgene Corporation Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.12.5 Celgene Corporation Recent Development
11.13 Diapharma.
11.13.1 Diapharma. Company Detail
11.13.2 Diapharma. Business Overview
11.13.3 Diapharma. Heparin-induced Thrombocytopenia Treatment Introduction
11.13.4 Diapharma. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.13.5 Diapharma. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
| ※参考情報 ヘパリン誘発性血小板減少症（HIT）は、抗凝固薬であるヘパリンの使用に関連して発生する重篤な副作用の一つであり、血小板数の著しい減少と血栓症のリスクが高まる状態です。この状態は、ヘパリンを投与された患者の中で、約1%から5%の割合で発生します。HITは、特に外科手術や重症疾患治療を受ける患者において、顕著に見られることがあります。 HITの定義は、ヘパリン投与後に血小板数が30%を超える減少が認められ、かつ、血栓症の合併が見られる場合を指します。血小板減少が見られるのは、通常、ヘパリン投与開始から5日目以降が多く、再投与を行った場合にはより早く発症することがあります。この状態は、特にアプローチが遅れると、致命的な結果を招く可能性があるため、医療従事者は早期の認識と対応が求められます。 HITの特徴的な症状としては、血小板の顕著な減少だけでなく、血栓症の発生が挙げられます。この血栓症は静脈性血栓症（深部静脈血栓症や肺塞栓症）や動脈性血栓症（心筋梗塞や脳血栓）として現れることがあります。HITによって生じる血栓症は、通常の血栓症よりも重篤であり、これがHITの大きな特徴です。 HITは、2つの型に分類されます。第一型HITは、軽度の血小板減少を伴い、ヘパリン投与後数日以内に発生することが多いですが、臨床的には問題とならないことが多いです。一方、第二型HITは、免疫介在性の反応として発生し、重篤な血小板減少と相関しており、血栓症のリスクが高まります。この第二型HITが治療の対象となります。 治療法としては、ヘパリンの使用を直ちに中止することが最優先となります。次に、代替の抗凝固薬として、ダルテパリンやエノキサパリンなどの低分子ヘパリンを用いる代わりに、直接経口抗凝固薬であるダビガトランやアピキサバンが選択されることが一般的です。また、抗血小板薬であるアスピリンを併用することも考慮されます。特に高リスクの患者群に対しては、治療が重要となります。 HITの治療においては、血小板数のモニタリングが欠かせません。治療効果を評価するためには、血小板数の回復を定期的に確認しながら、必要に応じて抗凝固薬の剤型や用量を調整することが求められます。また、HIT関連の血栓症を予防するための早期の介入も重要です。 関連技術としては、HITの診断には特異的な検査が導入されており、血液中に存在する抗PF4/ヘパリン抗体を検出するためのELISA法が広く用いられています。この検査は、HITの確定診断に寄与するものとして、非常に重要な役割を果たしています。さらに、臨床的な評価や診断基準を満たすためのスコアリングシステムも存在し、それによって患者のリスク評価を行うことが可能となります。 HITは、ヘパリンを使用する多くの医療現場で発生しうるため、医療従事者はその予防と管理についての知識を深めておく必要があります。HEPARIN（ヘパリン）を使用する際には、患者の基礎疾患やリスクファクターを考慮した上で、臨機応変な対応が求められます。また、最近の研究により、HITのメカニズムや新しい治療法についても明らかになりつつあり、今後の進展が期待されます。 HITの管理と治療には、患者の個々の状態に応じたアプローチが必要です。このため、多職種連携が重要であり、医師、看護師、薬剤師が協力して、個別の治療プランを策定し、実施することが求められます。治療が適切に行われることで、HITに関連する合併症のリスクを軽減し、患者の安全を確保することが可能です。 HITの知識を深めることで、医療従事者は、患者の安全を第一に考えた適切な管理を行うことができるでしょう。今後もHITに関する研究が進むことで、より効果的な治療法や予防策がもたらされることが期待され、血栓症による合併症から患者を守るための新たな手段が提供されることが望まれます。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
